drugset / Trial / NCT04082780
Rifamycin in Minimal Hepatic Encephalopathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifamycin SV MMX | Unknown | 600 mg | Oral |